Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4552894 | 0.87 | SLC6A3 (0.47) | SLC6A3SLC6A2SLC6A4CCR2PRCP | |
| SCHEMBL4553209 | 0.84 | SLC6A3 (0.47) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL27503119 | 0.83 | SLC6A3 (0.38) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL9341311 | 0.79 | SLC6A3 (0.52) | SLC6A3SLC6A2SLC6A4 | |
| Acetic Acid SCHEMBL29252813 | 0.79 | SLC6A2 (0.46) | SLC6A3SLC6A2SLC6A4CCR2GPR84 | |
| Acetic Acid SCHEMBL29252308 | 0.78 | SLC6A3 (0.45) | SLC6A3SLC6A2SLC6A4CCR2GPR84 | |
| Acetic Acid SCHEMBL29251586 | 0.78 | SLC6A3 (0.45) | SLC6A3SLC6A2SLC6A4CCR2PRCP | |
| SCHEMBL5718233 | 0.78 | SLC6A3 (0.43) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6843789 | 0.78 | SLC6A2 (0.52) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL9205681 | 0.77 | SLC6A3 (0.41) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1612207-B1 | Processes and intermediates for preparing 2-substituted piperidine stereoisomers | CELGENE CORP (US) | 2009-01-07 | — | — | EP | claimed |
| EP-1612207-B1 | Processes and intermediates for preparing 2-substituted piperidine stereoisomers | CELGENE CORP (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080269494-A1 | Process for the Preparation of Alpha-Aryl-Alpha-Piperid-2-Yl-Acetamides and the Acid Hydrolysis Thereof | ARCHIMICA S.R.L. (IT) | 2008-10-30 | — | — | US | disclosed |
| EP-1868996-A1 | A PROCESS FOR THE PREPARATION OF ALPHA-ARYL-ALPHA-PIPERID-2-YL-ACETAMIDES AND THE ACID HYDROLYSIS THEREOF | Archimica S.r.l. (IT) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006064052-A1 | A PROCESS FOR THE PREPARATION OF ALPHA-ARYL-ALPHA-PIPERID-2-YL-ACETAMIDES AND THE ACID HYDROLYSIS THEREOF | ARCHIMICA S.R.L. (IT) | 2006-06-22 | — | — | WO | disclosed |
| EP-1612207-A1 | Processes and intermediates for preparing 2-substituted piperidine stereoisomers | CELGENE CORPORATION (US) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269494-A1 | Process for the Preparation of Alpha-Aryl-Alpha-Piperid-2-Yl-Acetamides and the Acid Hydrolysis Thereof | ADRA2A, ARSA, CYP1A2 | SLC6A3 735/4885SLC6A2 388/4885SLC6A4 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.